Patrick Campbell

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.

The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.

New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Carla Nester, MD, provides perspective on the results of the VALIANT trial and how it informs the role of pegcetacoplan in C3G and IC-MPGN .

VALIANT trial data support pegcetacoplan as the first effective therapy for proteinuria, C3c staining, and eGFR stability in C3G and IC-MPGN patients.

Yale's KAT-AKI trial found personalized EHR alerts for AKI management improved clinician actions but didn't reduce progression, dialysis, or mortality rates in patients.

New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.

New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.

A posthoc analysis of the DUPLEX trial suggests patients with genetic FSGS may experience a more pronounced and sustained antiproteinuric response with sparsentan.

RIVUR analysis suggests recurrent UTIs in children with VUR may lower eGFR, even without kidney scarring, especially in those with multiple febrile infections.

Jonathan Barratt, PhD, discusses his excitement surrounding data and programming at the American Society of Nephrology's Kidney Week 2024, with a focus on IgAN.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.

Stephanie Christenson, MD, discusses the impact of recent regulatory approvals and pipeline movement for chronic obstructive pulmonary disease.

Linda Gillam, MD, MPH, discusses updates in the management of aortic stenosis, with a focus on use of TAVR.

Linda Gillam, MD, MPH, discusses the idea that the cardiology community may. be overtreating aortic stenosis.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

New research reveals amyl nitrite (poppers) use is linked to dermatitis, with perianal and perioral regions most affected.

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.

The FDA's decision to issue a CRL was announced on October 08, 2024 and cites issues with the timing of the facility inspection.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

Ruxolitinib cream offers an effective nonsteroidal treatment for mild to moderate atopic dermatitis, with proven efficacy and safety for sensitive skin areas.

Steve Nissen, MD, discusses how the cardiology community needs to learn from previous mistakes in uptake of LDL-C lowering therapies as it approaches an age of Lp(a)-lowering agents.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.